
HHS has launched a Kidney Care National Plan built around three priorities: preventing kidney failure, improving dialysis care while expanding patient choice, and reforming the transplant system. The department said its agencies will use the plan to guide policy, payment, research, regulatory and oversight actions, according to an American Hospital Association report on the Oct. 20 announcement.
The target is substantial. About 35.5 million U.S. adults, more than one in seven, have chronic kidney disease, and Medicare spent nearly $77 billion on CKD care for beneficiaries 66 and older in 2021, or roughly 24 percent of Medicare spending for that age group, based on federal data compiled by the National Institute of Diabetes and Digestive and Kidney Diseases.
What the Kidney Care National Plan Covers
HHS Secretary Robert F. Kennedy Jr. announced the plan at JPS Health Network in Fort Worth, Texas, framing it around earlier detection and expanded treatment and home care options. The three priorities, as described in published reports:
- Preventing kidney failure, including addressing underlying causes of kidney disease
- Improving dialysis care and expanding patient choice
- Reforming the transplant system through a National Transplant Expansion Strategy
The plan builds on a 2019 executive order, Advancing American Kidney Health, issued during the first Trump administration. Published reports indicate HHS has not released concrete targets, funding figures or timelines alongside the announcement.
Why Prevention Is the Hardest Piece
The prevention goal confronts a detection problem. Up to nine in 10 adults with CKD are unaware they have it, according to CDC data. More recent CDC estimates put the share of adults 20 and older with CKD who do not know it at about 87 percent.
Prevalence tracks closely with other chronic conditions, which is where prevention efforts would have to operate. CDC estimates CKD affects 38 percent of adults with diabetes, 41 percent of those with type 2 diabetes and 21 percent of adults with high blood pressure.
Disparities are pronounced. CKD prevalence is about 20 percent among non-Hispanic Black adults compared with 12 percent among non-Hispanic White adults, and reaches 34 percent among adults 65 and older.
Kidney Care Competition in Dialysis
The dialysis portion appears aimed at market structure. The plan seeks to ease barriers for companies that want to challenge established dialysis providers, according to reporting cited in published accounts, in a market where DaVita and Fresenius Medical Care together hold a combined share near 74 percent.
Both companies responded supportively while pushing back on parts of the premise. DaVita said it shares the administration’s urgency and that the plan reflects many of its priorities, but disagreed that kidney care lacks innovation or that scale is an obstacle. Fresenius backed the focus on innovation, home dialysis access and simplified transplant pathways, citing its hemodiafiltration work and a transplant referral program.
Home dialysis remains a minority of treatment. About 14.1 percent of dialysis patients were on home modalities at the end of 2021, up roughly 45 percent over the prior decade, based on United States Renal Data System figures.
Transplant System Reform
The transplant element continues enforcement already underway. HHS decertified Kentucky-based organ procurement organization Network for Hope in August, with Kennedy citing “persistent patient safety failures” identified in CMS and HRSA reviews after repeated warnings. The department decertified Life Alliance Organ Recovery Agency, part of University of Miami Health System, the previous September, and announced a broader organ transplant overhaul in July.
The need is measurable. More than 808,000 people are living with end-stage kidney disease, 68 percent on dialysis and 32 percent with a transplant. Some 90,323 people were on the kidney transplant waitlist as of November 2024, against 27,332 kidney transplants completed in 2023. Among patients first waitlisted in 2016, 46.3 percent had received a transplant within five years.
What It Means for Providers and Payers
The National Kidney Foundation called the plan “an important roadmap” and said prevention should be central. For health systems and payers, the practical implications depend on follow-through that has not yet been specified.
Prevention at scale would require screening programs in primary care, where most undiagnosed CKD sits, and payment models that reward slowing progression rather than treating failure. Dialysis competition policy could reshape referral relationships in markets dominated by two chains. Transplant reform continues to put organ procurement organizations under direct federal scrutiny. Each depends on specific regulations and payment changes that the plan, as announced, leaves for later.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
